Medical Information
Saudi Arabia
 

This medical Information website is intended only for Healthcare Professionals in the Kingdom of Saudi Arabia. This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Please choose the category that best describes you.

This content is intended for Healthcare professionals in Saudi Arabia. Would you like to proceed?

I am a healthcare professional registered to practice in KSAYes, I am a healthcare professional registered to practice in KSA
SelectI am a healthcare professional registered to practice in KSAYes, I am a healthcare professional registered to practice in KSA
I am not a healthcare professionalNo, go back to the patient portal
SelectI am not a healthcare professionalNo, go back to the patient portal
Non-Saudi Arabia residents click here.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Oral Presentation
Kristensen LE, Strober B, Poddubnyy D, Leung Y-Y, Jo H, Kwok K, Vranic I, Fleishaker D, Fallon L, Yndestad A, Gladman DD June 1, 2022 EULAR 2022 Psoriatic Arthritis

Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib

View Presentation
Poster
Giles JT, Charles-Schoeman C, Buch MH, Dougados M, Szekanecz Z, Ytterberg SR, Koch GG, Wu J, Wang C, Kwok K, Menon S, Chen Y, Cesur TY, Rivas JL, Yndestad A, Diehl A, Bhatt DL June 1, 2022 EULAR 2022 Rheumatoid Arthritis

Association between baseline statin treatment and major adverse cardiovascular events in patients with rheumatoid arthritis: a post hoc analysis of ORAL Surveillance

View Presentation
Poster
Wright GC, Mysler E, Chen Y-H, Kinch C, Yndestad A, Kwok K, Cadatal MJ, Germino R, Ogdie A June 1, 2022 EULAR 2022 Rheumatoid Arthritis

Impact of race on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of Phase 2, 3 and 3b/4 clinical trials

View Presentation
Poster
Waddington JC, Zhou R, Coleman O, Wundervald B, Parnell A, Mease PJ, Chandran V, Fallon L, Chapman D, Pollock R, Deng S, FitzGerald O, Pennington SR June 1, 2022 EULAR 2022 Psoriatic Arthritis

Mass spectrometry-based proteomics for the identification of candidate serum protein biomarkers that may predict treatment response in patients with psoriatic arthritis

View Presentation
Poster
Karpouzas G, Szekanecz Z, Baecklund E, Mikuls T, Bhatt DL, Shi H, Wang C, Sawyerr G, Chen Y, Menon S, Connell CA, Ytterberg SR, Mortezavi M June 1, 2022 EULAR 2022 Rheumatoid Arthritis

Relationship between disease activity and major adverse events in patients with rheumatoid arthritis on tofacitinib or TNF inhibitors: a post hoc analysis of ORAL Surveillance

View Presentation
Poster
Charles-Schoeman C, Buch MH, Dougados M, Bhatt DL, Giles JT, Ytterberg SR, Koch GG, Vranic I, Wu J, Wang C, Menon S, Rivas JL, Yndestad A, Connell CA, Szekanecz Z June 1, 2022 EULAR 2022 Rheumatoid Arthritis

Risk factors for major adverse cardiovascular events in patients aged ≥50 years with rheumatoid arthritis and ≥1 additional cardiovascular risk factor: a post hoc analysis of ORAL Surveillance

View Presentation
Oral Presentation
Dougados M, Taylor PC, Bingham CO, Fallon L, Brault Y, Roychoudhury S, Wang L, Kessouri M June 1, 2022 EULAR 2022 Rheumatoid Arthritis, Psoriatic Arthritis

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis with complete control of inflammation

View Presentation
Poster
Szekanecz Z, Giles JT, Buch MH, Ytterberg SR, Dougados M, Bhatt DL, Koch GG, Vranic I, Wu J, Wang C, Kwok K, Menon S, Rivas JL, Yndestad A, Connell CA, Charles-Schoeman C June 2, 2022 EULAR 2022 Rheumatoid Arthritis

Incidence of major adverse cardiovascular events stratified by geographic region and baseline cardiovascular risk: a post hoc analysis of ORAL Surveillance

View Presentation
Oral Presentation
Szekanecz Z, Charles-Schoeman C, Vranic I, Sahin B, Paciga SA, Wang Z, Hyde C, Martin D, Weitz JI June 3, 2022 EULAR 2022 Rheumatoid Arthritis

Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors

View Presentation
Oral Presentation
Dougados M, Charles-Schoeman C, Szekanecz Z, Giles JT, Ytterberg SR, Bhatt DL, Koch GG, Vranic I, Wu J, Wang C, Kwok K, Menon S, Connell CA, Yndestad A, Rivas JL, Buch MH June 3, 2022 EULAR 2022 Rheumatoid Arthritis

Impact of baseline cardiovascular risk on the incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme

View Presentation